To test whether SEMA7A promotes chemoresistance in breast cancer cells, we treated SEMA7A-overexpressing and knockdown MCF10DCIS mammosphere cultures with the chemotherapeutic drug, paclitaxel. Here, SEMA7A is linked to breast cancer.